Summary
A Phase III, open label, randomized, controlled, multicenter study to assess the safety and efficacy of the Study Drug monotherapy versus the physician’s choice to treat platinum-sensitive relapsed ovarian cancer.
Register to download
Embracing a Risk-based Approach
You may also be interested in:
Blog
Recommendations on Writing a Clinical Study Report for a Study Conducted During the COVID-19 Pandemic
The clinical study report (CSR) is a crucial document in the drug development and regulatory submission process that describes the background,…
Read Story
Case Study
Meeting Enrollment Goals Breast Cancer
An open-label, randomized, multi-center study to evaluate the use of Study Drug in the prevention of cancer treatment-related bone loss in…
View Resource
Case Study
Early Engagement Crucial to Develop Trial Design for Accelerated Schedule Vaccine Study
A case study describing PRA's involvement in an accelerated schedule vaccine study for poliomyelitis.
View Resource
View all related content and resources for Study Design
Explore Insights